Education
About Us
Working with TipRanks
Follow Us
Suven Pharmaceuticals Ltd. (IN:SUVENPHAR)
:SUVENPHAR
Total Valuation
Suven Pharmaceuticals Ltd. has a market cap or net worth of ₹406.44B. The enterprise value is ₹414.34B.
Market Cap₹406.44B
Enterprise Value₹414.34B
Share Statistics
Suven Pharmaceuticals Ltd. has 382,567,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding382,567,140
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Suven Pharmaceuticals Ltd.’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 8.27%.
Return on Equity (ROE)0.16
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)8.27%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee10.04M
Profits Per Employee2.88M
Employee Count1,193
Asset Turnover0.40
Inventory Turnover1.83
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio103.9
PS Ratio0.00
PB Ratio16.15
Price to Fair Value15.93
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio-5.41
Income Statement
In the last 12 months, Suven Pharmaceuticals Ltd. had revenue of 11.98B and earned 2.65B in profits. Earnings per share was 10.52.
Revenue11.98B
Gross Profit8.92B
Operating Income2.98B
Pretax Income3.44B
Net Income2.65B
EBITDA4.34B
Earnings Per Share (EPS)10.52
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Suven Pharmaceuticals Ltd. pays an annual dividend of ₹5, resulting in a dividend yield of ―
Dividend Per Share₹5
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.72
52-Week Price Change33.17%
50-Day Moving Average1.03K
200-Day Moving Average1.14K
Relative Strength Index (RSI)64.92
Average Volume (3m)8.79K
Important Dates
Suven Pharmaceuticals Ltd. upcoming earnings date is Aug 13, 2025, TBA (Confirmed).
Last Earnings DateMay 28, 2025
Next Earnings DateAug 13, 2025
Ex-Dividend DateSep 09, 2022
Financial Position
Suven Pharmaceuticals Ltd. as a current ratio of 2.43, with Debt / Equity ratio of 16.45%
Current Ratio2.43
Quick Ratio1.98
Debt to Market Cap<0.01
Net Debt to EBITDA0.45
Interest Coverage Ratio24.11
Taxes
In the past 12 months, Suven Pharmaceuticals Ltd. has paid 791.50M in taxes.
Income Tax791.50M
Effective Tax Rate0.23
Enterprise Valuation
Suven Pharmaceuticals Ltd. EV to EBITDA ratio is 62.77, with an EV/FCF ratio of 205.55.
EV to Sales22.73
EV to EBITDA62.77
EV to Free Cash Flow205.55
EV to Operating Cash Flow94.48
Balance Sheet
Suven Pharmaceuticals Ltd. has ₹6.56B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹6.56B billion.
Cash & Marketable Securities₹6.56B
Total Debt₹0.00
Net Cash-₹6.56B
Net Cash Per Share-₹17.14
Tangible Book Value Per Share₹44.57
Margins
Gross margin is 67.32%, with operating margin of 24.86%, and net profit margin of 22.11%.
Gross Margin67.32%
Operating Margin24.86%
Pretax Margin28.72%
Net Profit Margin22.11%
EBITDA Margin36.22%
EBIT Margin29.75%
Analyst Forecast
The average price target for Suven Pharmaceuticals Ltd. is ₹1,416.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target₹1,416.67
Price Target Upside27.89% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast13.91%
EPS Growth Forecast-10.80%